Anacor Pharma (ANAC) Tops Q4 EPS by 37c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- S&P 500 ends down; Apple dips ahead of quarterly report
- Apple beats quarterly estimates for profit and revenue
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops 7% as Iran signals openness to peace talks
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Anacor Pharmaceuticals (ANAC) PT Raised to $57 at Jefferies
March 13, 2015 8:41 AM EDTJefferies analyst David Steinberg reiterated a Buy rating and lifted is price target on Anacor Pharmaceuticals (NASDAQ: ANAC) to $57.00 (from $41.00) following Q4 results.
Steinberg commented, "ANAC reported a narrower Q4 loss primarily due to the earlier recognition of Kerydin revs (see details). More... More
Anacor Pharmaceuticals (ANAC) PT Raised to $60 at Wedbush
March 13, 2015 7:13 AM EDTWedbush analyst David Nierengarten reiterated an Outperform rating and boosted his price target on Anacor Pharmaceuticals (NASDAQ: ANAC) to $60.00 (from $50.00) after in 4Q14, its first full quarter of sales, Kerydin achieved about $10M in sales, beating the firm's $7.8M estimate.
Nierengarten commented... More



